Scientific Exhibit at American Epilepsy Society (AES) Annual Meeting (Dec.7, 2025)
- Overview of Bright Minds Biosciences. Pioneering Serotonin Pharmacology
- BMB-101 and Biased 5-HT2C Agonism. A Novel Approach for Sustained Epilepsy Management
- 5-HT2C Agonism: Multiple Animal Models Supporting the Efficacy in Developmental and Epileptic Encephalopathy (DEE) Indications
- 5-HT2C Agonism: Efficacy in 6-Hz and DBA/2 Mouse Models Supports Utility in Other Epilepsy Syndromes
- Safety, Tolerability, and Pharmacokinetics of Novel 5-HT2C Agonist BMB-101 (Phase 1 Clinical Study)
- A phase 1 clinical study of BMB-101 shows linear PK and a reduced rate of somnolence and GI/Urinary side effects compared to other 5-HT2C agonists
- BMB-101 in Absence Seizures and Developmental and Epileptic Encephalopathy (DEE): An Open-Label Phase 2 Study
- Selective 5-HT2C Agonist BMB-101 in the Treatment of Patients with Prader-Willi Syndrome (PWS)